Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis

Arthritis Care and Research

Volumn 62, Issue 6, 2010, Pages 821-825

  Zulian, Francesco ^a   Balzarin, Marta ^a   Falcini, Fernanda ^b   Martini, Giorgia ^a   Alessio, Maria ^c   Cimaz, Rolando ^d   Cimino, Luca ^e   Zannin, Maria Elisabetta ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTHRITIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALE; MYCOSIS; OPTIC NEURITIS; PRESCHOOL CHILD; REMISSION; SCHOOL CHILD; SKIN MANIFESTATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UVEITIS;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCONJUGATES; MALE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 77953108648     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20115     Document Type: Article

References (19)

1. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007;56:647-657 (Pubitemid 46271991)
2. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007;17:743-748
3. Tappeiner C, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 2009;23:1192-1198
4. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007;91:180-184 (Pubitemid 46202865)
5. Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease [letter]. Ann Rheum Dis 2007;66:840-841 (Pubitemid 46846714)
6. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-324
7. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353: 1114-1123 (Pubitemid 41317434)
8. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-391
9. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J Rheumatol 2008;35:1897-1898
10. Jabs DA, Nussenblatt RB, Rosenbaum JT, and the Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 2005;140:509-516
11. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-3252 (Pubitemid 47585419)
12. Reddy AR, Backhouse OC. Does etanercept induce uveitis? [letter]. Br J Ophthalmol 2003;87:925.
13. Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006;14:145-150 (Pubitemid 43890770)
14. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:645-646 (Pubitemid 37236461)
15. Monnet D, Moachon L, Dougados M, Brezin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:393-397
16. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agents. J Pediatr 2006;149:833-836
17. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-550 (Pubitemid 46580481)
18. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002;13:559-575 (Pubitemid 34106301)
19. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000;165:5041-5047